-
Publication Venue For
-
Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report..
18:1109-1118.
2022
-
Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease..
18:1260-1278.
2022
-
Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research..
18:1038-1046.
2022
-
Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease.
2022
-
Clinical research in dementia: A perspective on implementing innovation.
2022
-
A Bayesian perspective on Biogen's aducanumab trial.
2022
-
Traumatic brain injury and dementia risk in male veteran older twins-Controlling for genetic and early life non-genetic factors.
2022
-
APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.
2022
-
How good are medical and death records for identifying dementia?
2021
-
A proof of concept study towards multi-omics-based computational drug repositioning in Alzheimer's disease.
17:e056673.
2021
-
APOE, TOMM40, and Sex Interactions on Neural Network Connectivity..
17 Suppl 12:e058171.
2021
-
Amylin-mediated regulation of LRP1 by miR-103/107 impairs β-amyloid efflux.
17:e052576.
2021
-
Amyloid-β removal from the brain is blocked by circulating amyloid-forming amylin secreted by the pancreas.
17:e053782.
2021
-
Analysis of pleiotropic genetic effects on cognitive decline and systemic inflammation in the Women's Health Initiative Memory Study.
17:e050784.
2021
-
Bioinformatics pipeline to advance the identification of transcription regulatory variants in LOAD noncoding regions.
17:e050665.
2021
-
Investigating the importance of acylcarnitines in Alzheimer's disease.
17:e056647.
2021
-
Parallel single-nucleus chromatin accessibility and transcriptomic profiling of human late-onset Alzheimer's disease brains.
17:e057261.
2021
-
Percutaneous vagus nerve stimulation modulates glia activity and rescues acute Aβ deposition in a mouse model of delirium superimposed on dementia.
17:e056571.
2021
-
The metabolic landscape of brain alterations in Alzheimer's disease.
17:e054793.
2021
-
The ε4-bearing TOMM40-APOE-APOC1 haplotype but not the ε4 allele confers an exceptionally high risk of Alzheimer's disease.
17:e050617.
2021
-
Recruitment of a multi-site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trial..
17:1808-1817.
2021
-
Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study..
17:1619-1627.
2021
-
TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks..
17:1287-1296.
2021
-
CVN-AD Alzheimer's mice show premature reduction in neurovascular coupling in response to spreading depression and anoxia compared to aged controls..
17:1109-1120.
2021
-
How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease..
17:917-919.
2021
-
Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways..
17:561-573.
2021
-
Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau..
16:1234-1247.
2020
-
Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome..
16:1280-1292.
2020
-
Racially diverse participant registries to facilitate the recruitment of African Americans into presymptomatic Alzheimer's disease studies..
16:1107-1114.
2020
-
Further understanding the connection between Alzheimer's disease and Down syndrome..
16:1065-1077.
2020
-
New Thinking About Thinking, Part 3. Advice on preparing a successful manuscript for Alzheimer's & Dementia..
16:949-952.
2020
-
International drive to illuminate delirium: A developing public health blueprint for action..
16:711-725.
2020
-
Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia..
16:734-749.
2020
-
Bioinformatics strategy to advance the interpretation of Alzheimer's disease GWAS discoveries: The roads from association to causation..
15:1048-1058.
2019
-
Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms..
15:194-204.
2019
-
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers..
15:232-244.
2019
-
A systems-based model of Alzheimer's disease..
15:168-171.
2019
-
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome..
15:76-92.
2019
-
Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease..
15:8-16.
2019
-
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative..
15:106-152.
2019
-
New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia..
14:703-706.
2018
-
A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data..
14:644-651.
2018
-
The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes..
14:692-698.
2018
-
Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework..
14:532-534.
2018
-
Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter?.
14:454-461.
2018
-
Evidence for brain glucose dysregulation in Alzheimer's disease..
14:318-329.
2018
-
Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study..
14:280-292.
2018
-
Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline..
13:1380-1388.
2017
-
Family history and TOMM40 '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts..
13:1217-1225.
2017
-
Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies..
13:1237-1250.
2017
-
Innovation in care for individuals with cognitive impairment: Can reimbursement policy spread best practices?.
13:1168-1173.
2017
-
Metabolic network failures in Alzheimer's disease: A biochemical road map..
13:965-984.
2017
-
The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease..
13:828-838.
2017
-
Transethnic genome-wide scan identifies novel Alzheimer's disease loci..
13:727-738.
2017
-
The Vascular Impairment of Cognition Classification Consensus Study..
13:624-633.
2017
-
Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease..
12:687-694.
2016
-
Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials..
12:631-632.
2016
-
Report on milestones for care and support under the U.S. National Plan to Address Alzheimer's Disease..
12:334-369.
2016
-
Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses..
11:1439-1451.
2015
-
A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression..
11:1133-1143.
2015
-
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans..
11:792-814.
2015
-
A comparison of neuropsychological performance between US and Russia: preparing for a global clinical trial..
10:760-768.e1.
2014
-
African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles..
10:592-601.e2.
2014
-
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease..
10:S430-S452.
2014
-
The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes..
10:541-551.
2014
-
Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study..
10:366-371.
2014
-
Microvascular network alterations in the retina of patients with Alzheimer's disease..
10:135-142.
2014
-
Personality and risk of Alzheimer's disease: new data and meta-analysis..
10:179-186.
2014
-
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging..
9:S72-S83.
2013
-
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's disease..
9:284-294.
2013
-
TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial..
9:132-136.
2013
-
Longitudinal modeling of cognitive aging and the TOMM40 effect..
8:490-495.
2012
-
Cerebral white matter disease is associated with Alzheimer pathology in a prospective cohort..
8:S71-S77.
2012
-
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging..
8:381-388.
2012
-
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit..
8:445-452.
2012
-
Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression..
8:180-187.
2012
-
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers..
7:386-395.e6.
2011
-
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype..
7:456-465.
2011
-
Metabolomic changes in autopsy-confirmed Alzheimer's disease..
7:309-317.
2011
-
National estimates of the prevalence of Alzheimer's disease in the United States..
7:61-73.
2011
-
Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1..
7:15-34.
2011
-
Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2..
7:35-52.
2011
-
Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 1..
7:94-109.
2011
-
Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States..
7:74-79.
2011
-
An examination of Alzheimer's disease case definitions using Medicare claims and survey data..
6:334-341.
2010
-
Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers..
6:303-311.
2010
-
Genetic variation at a single locus and age of onset for Alzheimer's disease..
6:125-131.
2010
-
Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites..
5:445-453.
2009
-
Midlife activity predicts risk of dementia in older male twin pairs..
4:324-331.
2008
-
Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study..
4:223-227.
2008
-
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years..
4:96-109.
2008
-
Job demands and dementia risk among male twin pairs..
3:192-199.
2007
-
Modifying dementia risk and trajectories of cognitive decline in aging: the Cache County Memory Study..
2:257-260.
2006
-
The reciprocal risks of stroke and cognitive impairment in an elderly population..
2:171-178.
2006
-
Perspective on a pathogenesis and treatment of Alzheimer's disease..
2:59-70.
2006
-
Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples..
2:2-11.
2006
-
Identification of VaD and AD prodromes: the Cache County Study..
1:19-29.
2005